Pfizer's drug succeeds in late-stage blood cancer trial

[March 12, 2024]  (Reuters) -Pfizer said on Tuesday a combination treatment using its drug, Adcetris, met the main goal of a late-stage study of extending survival in patients with a type of blood cancer.

The combination therapy consisting of Adcetris and two other drugs was statistically significant compared to a placebo in extending survival in patients with the most common type of lymphoma known as diffuse large B-cell lymphoma.

Pfizer gained the drug, already approved to treat other types of lymphomas, through its $43 billion purchase of Seagen last year.

The U.S. drugmaker plans to discuss a submission for approval to treat these type of patients with regulators, it said, paving the way for a possible eighth approval for the drug.

Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

(Reporting by Pratik Jain; Editing by Shailesh Kuber and Sriraj Kalluvila)

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.